Clofarabine for advanced bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests the drug clofarabine in people with advanced bladder cancer that has spread or cannot be removed by surgery. It is for those who have already tried standard treatments or chose not to have them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bladder cancer that has spread or cannot be surgically removed.
- You have already tried standard treatment or decided not to take it.
- You are 18 years or older.
- You are generally able to care for yourself (performance status 0-2).
- Your blood counts are within a certain range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, 9MW2821, against standard chemotherapy for people with advanced bladder cancer that has gotten worse after previous treatments. It aims to see if the new drug works better.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
This trial tests a new drug, nadofaragene firadenovec, which uses a harmless virus to deliver a signal that helps your immune system fight low-grade cancer in the upper part of the urinary tract (the kidney area). It's given directly into the kidney through a small tube, and may avoid more invasive surgery.
This Phase 2 study compares two chemotherapy medicines—clofarabine and fludarabine—given at a reduced intensity before an allogeneic stem cell transplant. It aims to see which regimen works better and is safer for people with AML who are eligible for this transplant approach.
This trial tests a new combination of two medications, SHR-A2102 and adebrelimab, for people with advanced bladder cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Advanced Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.